Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences or HGS and Xencor have reported a collaboration agreement under which Xencor will apply its proprietary XmAb humanization and optimization technologies to enhance the pharmacologic properties of monoclonal antibodies developed by HGS.
Subscribe to our email newsletter
Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional payments including development and commercial milestones, and royalties on any products commercialized under the agreement. HGS will be responsible for all preclinical and clinical development, manufacturing and commercialization. Financial terms were not disclosed.
Bassil Dahiyat, president and CEO of Xencor, said: “This collaboration further validates the breadth of our XmAb technology platform. Our proprietary tools optimize the complete antibody structure, including the Fc region to improve potency and half-life and variable region humanization and affinity optimization.”